Technical Analysis for NVNO - enVVeno Medical Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.78 | -0.42% | -0.02 |
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Resistance | Bearish | -0.42% | |
| Oversold Stochastic | Weakness | -0.42% | |
| Fell Below 200 DMA | Bearish | 0.42% | |
| Narrow Range Bar | Range Contraction | 0.42% | |
| Down 3 Days in a Row | Weakness | 0.42% | |
| Down 4 Days in a Row | Weakness | 0.42% | |
| Oversold Stochastic | Weakness | 0.42% | |
| Stochastic Reached Oversold | Weakness | -2.85% | |
| Gapped Up | Strength | -2.85% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 6 hours ago |
| Up 2% | about 6 hours ago |
| 200 DMA Resistance | about 7 hours ago |
| Fell Below Previous Day's Low | about 7 hours ago |
| 200 DMA Support | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
enVVeno Medical Corporation Description
enVVeno Medical is an Irvine, California based medical device company focused on the development of innovative bioprosthetic (tissue-based) solutions to improve the standard of care in the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class implant being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). In healthy patients, valves inside the veins of the leg assist in propelling blood up the leg, and back to the heart and lungs. Affecting approximately 2.4 million people in the United States, CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Implanted into the femoral vein, the VenoValve is designed to act as a one-way valve, to help restore proper blood flow in the leg. The VenoValve is currently being evaluated in the SAVVE pivotal study with data expected in late 2022.
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Vascular Disease Ulcer Veins Circulatory System Angiology Cardiovascular System Chronic Venous Insufficiency Insufficiency Venous Insufficiency Venous Ulcer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.97 |
| 52 Week Low | 2.51 |
| Average Volume | 147,008 |
| 200-Day Moving Average | 4.83 |
| 50-Day Moving Average | 5.49 |
| 20-Day Moving Average | 5.19 |
| 10-Day Moving Average | 4.98 |
| Average True Range | 0.30 |
| RSI (14) | 35.90 |
| ADX | 22.55 |
| +DI | 13.61 |
| -DI | 23.46 |
| Chandelier Exit (Long, 3 ATRs) | 5.11 |
| Chandelier Exit (Short, 3 ATRs) | 5.62 |
| Upper Bollinger Bands | 5.78 |
| Lower Bollinger Band | 4.60 |
| Percent B (%b) | 0.15 |
| BandWidth | 22.66 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.16 |
| MACD Histogram | -0.0465 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.09 | ||||
| Resistance 3 (R3) | 5.10 | 5.02 | 5.04 | ||
| Resistance 2 (R2) | 5.02 | 4.94 | 5.01 | 5.02 | |
| Resistance 1 (R1) | 4.90 | 4.89 | 4.85 | 4.88 | 5.00 |
| Pivot Point | 4.81 | 4.81 | 4.79 | 4.80 | 4.81 |
| Support 1 (S1) | 4.69 | 4.73 | 4.65 | 4.68 | 4.56 |
| Support 2 (S2) | 4.61 | 4.68 | 4.60 | 4.54 | |
| Support 3 (S3) | 4.49 | 4.61 | 4.52 | ||
| Support 4 (S4) | 4.47 |
